美国FDA撤销此前决定 同意审核莫德纳mRNA流感疫苗

Core Viewpoint - Moderna has engaged in further discussions with regulatory authorities and announced that the FDA will accept its application for the market approval of an mRNA-based influenza vaccine after initially rejecting it due to flaws in the study design [1] Group 1 - The FDA initially rejected Moderna's application for the new influenza vaccine, citing defects in the study design [1] - Following subsequent communications, the FDA reversed its decision and agreed to initiate the review process for the vaccine [1]